



June 4, 2026

Dear DMD Community:

We would like to share an update on the planned AOC 1045 clinical trial for individuals with Duchenne muscular dystrophy amenable to exon 45 skipping (DMD45).

First, we want to thank the Duchenne community — including families, advocates, clinicians, and trial sites — for your continued engagement, questions, and feedback as we work to advance this program. Your partnership and input are incredibly important to us.

Based on our current planning, we now expect the study to begin closer to the first half of 2027. We acknowledge that this updated timeline may differ from earlier expectations, particularly for families who have been looking forward to new research and clinical trial opportunities.

This updated timeline reflects our commitment to taking the time needed to strengthen the study and ensure we move forward as thoughtfully as possible. Over the past several months, we have received valuable feedback from clinicians and the broader community about aspects of trial design. We are using that feedback to make changes intended to better support participants, families, and study sites. We are doing this to enter the study with the strongest possible foundation.

While this means the study will begin later than originally hoped, the AOC 1045 program is continuing to move forward. We believe these additional steps are important to help position the study for success and, most importantly, for meaningful impact for people living with Duchenne and their families.

We remain committed to keeping the community informed as plans progress, and we deeply appreciate your patience, trust, and ongoing partnership.

Sincerely,

The Avidity Team, a Novartis company

medinfo@aviditybio.com

[FA-11693686]